Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BIONET Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	18.3yrs

Son yönetim güncellemeleri

Recent updates

Should You Investigate BIONET Corp. (GTSM:1784) At NT$43.50?

Apr 10

If You Had Bought BIONET (GTSM:1784) Shares Three Years Ago You'd Have Earned 46% Returns

Feb 10

CEO

BIONET CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shao-Hua Huang	Independent Director	17.9yrs	Veri yok	0.026% NT$ 1.3m
John Wagner	Member of Advisory Board	no data	Veri yok	Veri yok
Wen Yan	Independent Director	18.3yrs	Veri yok	Veri yok
Zheng Huang	Director	19.8yrs	Veri yok	Veri yok
Cheng-Hsian Coi	Director	17yrs	Veri yok	3.83% NT$ 197.8m
Wen Zhang	Director	21.5yrs	Veri yok	1.9% NT$ 98.3m
Cui Zhang	Supervisor	24.2yrs	Veri yok	Veri yok
Zhao Fen Zhang	Supervisor	17yrs	Veri yok	Veri yok
Han Zhang	Director	18.3yrs	Veri yok	Veri yok
Shi Liang	Director	10.6yrs	Veri yok	0.51% NT$ 26.2m
Cheng-Hsien Tsai	Chairman of the Board	no data	Veri yok	Veri yok
Han Tung Chang	Director	no data	Veri yok	Veri yok

18.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1784 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 18.3 yıldır).

BIONET Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

BIONET Corp., Annual General Meeting, Jun 19, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Now 23% overvalued after recent price rise

Upcoming dividend of NT$0.71 per share

Second quarter 2024 earnings released: EPS: NT$0.35 (vs NT$0.67 in 2Q 2023)

Investor sentiment deteriorates as stock falls 17%

Now 23% undervalued

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

First quarter 2024 earnings released: EPS: NT$0.47 (vs NT$0.49 in 1Q 2023)

Investor sentiment improves as stock rises 18%

BIONET Corp., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: NT$1.67 (vs NT$0.80 in FY 2022)

Third quarter 2023 earnings released: EPS: NT$0.40 (vs NT$0.34 in 3Q 2022)

Upcoming dividend of NT$0.70 per share at 1.0% yield

Second quarter 2023 earnings released: EPS: NT$0.67 (vs NT$0.15 in 2Q 2022)

New major risk - Share price stability

Less than half of directors are independent

Upcoming dividend of NT$0.49 per share

Second quarter 2022 earnings released: EPS: NT$0.15 (vs NT$0.25 in 2Q 2021)

First quarter 2022 earnings released: EPS: NT$0.10 (vs NT$0.25 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$0.56 (vs NT$0.27 in FY 2020)

Third quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.033 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.25 (vs NT$0.003 loss in 2Q 2020)

Upcoming dividend of NT$0.18 per share

First quarter 2021 earnings released: EPS NT$0.25 (vs NT$0.11 in 1Q 2020)

Should You Investigate BIONET Corp. (GTSM:1784) At NT$43.50?

Full year 2020 earnings released: EPS NT$0.27 (vs NT$0.14 in FY 2019)

If You Had Bought BIONET (GTSM:1784) Shares Three Years Ago You'd Have Earned 46% Returns

New 90-day low: NT$35.85

New 90-day high: NT$42.95

Third quarter 2020 earnings released: EPS NT$0.03

New 90-day low: NT$38.35

First half earnings released

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş